Occupational Therapists in Hamilton, MI Accepting Medicare
5 Occupational Therapists found. Showing 1 - 5
 Mrs. Rebecca Sue Childress, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3491 Lincoln Rd, Hamilton, MI 49419 Phone: 269-751-2150 |
Melissa Sue Hands, MSOT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3491 Lincoln Rd, Hamilton, MI 49419 Phone: 616-392-3197 |
 Mr. Robert Dale Nye, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3491 Lincoln Rd., Hamilton, MI 49419 Phone: 269-751-2150 |
Kimberly Frances Counterman, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3491 Lincoln Rd, Hamilton, MI 49419 Phone: 269-751-2150 Fax: 269-751-2140 |
Torrie Sue Ballard, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3491 Lincoln Rd, Hamilton, MI 49419 Phone: 269-751-2150 |
News Archive
Circulating tumor cells can reveal genetic signature of dangerous lung cancers
Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.
COVID-19 and immunodeficiency
COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly infectious disease. As of today, over 170,000 people worldwide have succumbed to the infection. Reports have shown that some comorbidities and illnesses raise the risk of getting infected and also influence the severity of the disease. Having a compromised immune system can also drastically raise the risk of getting COVID-19.
Fourth-quarter and fiscal year end 2009 results announced by Palatin Technologies
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
PSA test distress, study urges caution
A new study wants men to be informed about risks associated with screening for prostate cancer. The research has brought out that the prostate cancer tests can cause significant psychological distress to the men undergoing the screening. 330 men were studied by the University of Bristol as they underwent the tests and after they finished.
CytRx granted European patent for tumor-targeting linker platform technology
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.
› Verified 5 days ago